Dopamine Agonist Therapy in Advanced Parkinson’s Disease

Dopamine Agonist Therapy in Advanced Parkinson’s Disease

Bibliographic Details
Main Author:	Heinz Reichmann
Format:	Article
Language:	English
Published:	Korean Movement Disorder Society 2009-05-01
Series:	Journal of Movement Disorders
Online Access:	http://e-jmd.org/upload/jmd-2-1-10-3.pdf

Similar Items

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01)

The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01)

Dopamine agonists and risk: Impulse control disorders in Parkinson's; Disease
by: Voon, V, et al.
Published: (2011)

Dopamine agonists and risk: impulse control disorders in Parkinson's disease.
by: Voon, V, et al.
Published: (2011)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01)

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01)

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
by: Hiu Fung Wu, et al.
Published: (2024-01-01)

Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s
by: McIntosh, E, et al.
Published: (2021)

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
by: Unrath Alexander, et al.
Published: (2009-06-01)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
by: Joyce P.M. van der Vegt, et al.
Published: (2020-01-01)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
by: Mohammad Edrees Mohammad, et al.
Published: (2021-01-01)

Dopamine D<sub>1</sub> Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
by: Mechelle M. Lewis, et al.
Published: (2023-05-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
by: Stuart H. Isaacson, et al.
Published: (2023-01-01)

Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson′s Disease
by: Li-Min Zhang, et al.
Published: (2015-01-01)

Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
by: Zachary K. Christian, et al.
Published: (2020-09-01)

Dopamine Agonists for Pituitary Adenomas
by: Odelia Cooper, et al.
Published: (2018-08-01)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
by: Grossman, A, et al.
Published: (1985)

Dopaminergic agonists in Parkinson's disease
by: A. Alonso Cánovas, et al.
Published: (2014-05-01)

Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients
by: Marios Politis, et al.
Published: (2017-01-01)

Effect of dopamine therapy on nonverbal affect burst recognition in Parkinson's disease.
by: Julie Péron, et al.
Published: (2014-01-01)

Role of dopamine in the pathophysiology of Parkinson’s disease
by: Zhi Dong Zhou, et al.
Published: (2023-09-01)

Dopamine dysregulation syndrome in Parkinson’s disease
by: A V Nikitina, et al.
Published: (2013-03-01)

The use of the dopamine agonist cabergoline in the therapy of surgically induced endometriosis in rats
by: M.I. Yarmolinskaya, et al.
Published: (2018-12-01)

Cushing’s Disease : Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline
by: Omayma ElShafie, et al.
Published: (2012-11-01)

The outcome of macroprolactinomas resistant to dopamine agonists
by: Coculescu, M, et al.
Published: (2005)

Impulse control disorders and dopamine agonists
by: D. Martins, et al.
Published: (2021-04-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials
by: Xinglin Ruan, et al.
Published: (2021-10-01)

Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
by: Satoshi Goto, et al.
Published: (2023-04-01)

α-Synuclein and dopamine at the crossroads of Parkinson's disease.
by: Venda, L, et al.
Published: (2010)

Impaired dopamine metabolism in Parkinson’s disease pathogenesis
by: Anna Masato, et al.
Published: (2019-08-01)

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
by: Alexandre Iarkov, et al.
Published: (2020-01-01)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
by: Sinn, D, et al.
Published: (1985)

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
by: U. Shivraj Sohur, et al.
Published: (2018-10-01)

The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.
by: Luis F Razgado-Hernandez, et al.
Published: (2015-01-01)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
by: M.L. Costa, et al.
Published: (2022-06-01)

Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01)

Parkinson’s disease and translational research
by: Elisabeth Dinter, et al.
Published: (2020-12-01)